Company intelligence / Profile preview

Guangzhou Ruixin Biotechnological

Guangzhou, Guangdong, Chinaruixinbang.en.alibaba.com ↗

Ownership: Private
Development stage: Other

Overview

The company has initiated an early phase clinical trial for its induced pluripotent stem cell-derived natural killer (iNK) cell therapy targeting relapsed and refractory acute myeloid leukemia. The trial aims to evaluate safety and preliminary efficacy in adults with AML who have failed at least two prior therapies. As of June 2025, the study was not yet recruiting and no clinical results are available.

Therapeutic areas: Oncology
Modalities: Induced pluripotent stem cell derived natural killer cell therapy (iNK cell therapy)Cell therapyStem cell therapy
Industry: Biotech

Partnerships

Not disclosed/publicly available.

Beyond the preview

Go deeper on Guangzhou Ruixin Biotechnological.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Ruixin Biotechnological.

Explore the full profile